Next Article in Journal
DNA Barcoding Identification of Angelicae Sinensis Radix and Its Adulterants Based on Internal Transcribed Spacer 2 Region and Secondary Structure Prediction
Previous Article in Journal
Reduced Sensorimotor, Working Memory, and Episodic Memory Abilities in Aging Female FMR1 Premutation Carriers with and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 16
Issue 11
10.3390/genes16111332
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Study of Hirustasin Superfamily Gene Expression in Two Medicinal Leeches, Hirudinaria manillensis and Whitmania pigra

by
Rujiao Sun
1,
Rui Ai
1,
Jingjing Yin
1,
Jianli Cheng
1,
Zuhao Huang
1,
Lizhou Tang
2,
Zichao Liu
3,
Qingqian Zeng
4,
Fang Zhao
1,* and
Gonghua Lin
1,4,*
1
School of Life Sciences, Key Laboratory of Jiangxi Province for Biological Invasion and Biosecurity, Jinggangshan University, Ji’an 343009, China
2
College of Life Sciences, Jiangxi Normal University, Nanchang 330022, China
3
School of Agronomy and Life Sciences, Kunming University, Kunming 650214, China
4
Guangdong Institute of Traditional Chinese Medicine, Guangzhou 510655, China
*
Authors to whom correspondence should be addressed.
Genes 2025, 16(11), 1332; https://doi.org/10.3390/genes16111332
Submission received: 2 October 2025 / Revised: 29 October 2025 / Accepted: 4 November 2025 / Published: 5 November 2025
(This article belongs to the Section Animal Genetics and Genomics)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Leeches constitute a pharmacologically significant animal group in traditional medicine due to their antithrombotic peptides, which include numerous members of the hirustasin gene superfamily. However, a comparative expression profile of this pharmaceutically important family across different leech species is lacking. Methods: This study conducted a comparative transcriptomic analysis of hirustasin gene superfamily expression in the hematophagous leech Hirudinaria manillensis and the non-hematophagous leech Whitmania pigra. Results: The total expression of the hirustasin gene superfamily, quantified as transcripts per million (TPM), showed no significant difference (p = 0.237) between H. manillensis (11,802.60 ± 1596.59) and W. pigra (8623.12 ± 965.96). However, both species exhibited pronounced intergenic expression heterogeneity. Five dominantly expressed genes (TPM > 1000) in H. manillensis and three in W. pigra were identified, collectively comprising 81% and 62% of the total hirustasin gene superfamily expression per species, respectively. Critically, the dominantly expressed genes exhibited no phylogenetic correspondence between species. Integrating expression profiles with phylogenetic reconstruction identified five high-potential candidate genes: poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, and bdellastasin_Wpig. Population-level analysis revealed marked population-specific expression patterns in H. manillensis, contrasting with minimal inter-population divergence in W. pigra. Nevertheless, geographically distinct populations of both species showed significant variation in the expression of their respective dominantly expressed genes. Conclusions: These findings provide a set of high-priority candidate genes and insights into their expression characteristics, serving as a starting point for subsequent functional validation and, when integrated with other screening methods, for future antithrombotic drug discovery.

1. Introduction

The incidence and mortality of cardiovascular diseases (CVDs) have continued to increase over the past three decades, mainly due to factors such as hypertension, dietary risks, and hypercholesterolemia [1,2,3]. Thrombosis, one of the major pathogenic mechanisms of CVD, can lead to ischemia, infarction, and organ dysfunction [4]. Although existing antithrombotic drugs are widely used in clinical practice, they are often accompanied by adverse effects such as bleeding and hepatotoxicity [5,6]. Therefore, the development of safe and effective natural antithrombotic agents has become an important research direction.
Medicinal leeches have long been used to prevent and treat blood stasis and thrombotic diseases [7,8,9], and they represent an important group of animal-derived medicinal materials. Among them, Whitmania pigra (Whitman, 1884) and Hirudinaria manillensis (Lesson, 1842) are the two most common leech species in the Chinese medicinal market. W. pigra has been officially recognized as the basic source species of “Shuizhi” in the Pharmacopoeia of the People’s Republic of China (PPRC), whereas H. manillensis, despite exhibiting potent anticoagulant activity, has not yet been included [10,11,12,13]. The differences between these two species in feeding habits (hematophagous vs. non-hematophagous) and regulatory legitimacy suggest that their anticoagulant functions may originate from molecular-level variations. In particular, members of the hirustasin gene superfamily, which function as serine protease inhibitors in the salivary glands of leeches, play key roles in anticoagulation. Therefore, a comparative analysis of hirustasin gene expression between these two medicinal leeches may help elucidate the molecular basis of their anticoagulant activity and provide insights for the scientific identification of basic source species and the development of antithrombotic drugs.
Leeches maintain blood flow by secreting various bioactive substances with anticoagulant, fibrinolytic, and anti-inflammatory properties, the types and abundances of which are closely related to their feeding characteristics [14,15]. To date, multiple antithrombotic components have been identified in leeches, such as antistasin, hirudin, guamerin, and hirustasin [15,16]. Hirustasin, first isolated in 1994 from Hirudo medicinalis [17], inhibits trypsin, chymotrypsin, tissue kallikrein, and neutrophil-derived cathepsin G. Owing to high sequence/functional homology, proteins including hirustasin [17], guamerin [18], bdellastasin [19], poecistasin [20], piguamerin [21], and uncharacterized hirustasin-like proteins [22] constitute the hirustasin gene superfamily. These proteins typically contain a signal peptide and ten conserved cysteine residues [22]. Primarily co-expressed in leech salivary glands, they synergistically inhibit coagulation and proteolysis, significantly enhancing leech anticoagulant efficacy and underscoring the need for systematic research on this gene superfamily.
To optimize the utilization of medicinal leech resources, it is essential to return to their core attribute as daodi medicinal materials—ensuring both quality and therapeutic efficacy. In the traditional Chinese medicine (TCM) system, leeches are regarded as important animal-derived daodi medicinal materials due to their remarkable blood-activating, stasis-resolving, anticoagulant, and thrombolytic properties [23]. Daodi medicinal materials refer to Chinese medicinal substances cultivated, harvested, and processed under specific natural conditions, ecological environments, and traditional techniques, whose quality and clinical efficacy are generally superior to those of the same species produced in other regions, thus earning high esteem in TCM clinical practice [24,25]. This unique quality advantage, associated with specific geographic origins, underscores the importance of elucidating the intrinsic pharmacological material basis of leeches as daodi medicinal materials—particularly the expression characteristics of key antithrombotic components such as the hirustasin gene superfamily. Understanding the potential differences in the expression of these critical bioactive components between leeches of different species (e.g., W. pigra vs. H. manillensis) or from different production areas is a pivotal step toward safeguarding and enhancing the quality and efficacy of daodi medicinal materials, and ultimately provides a key basis for optimizing the development and utilization of medicinal leech resources and for screening efficient antithrombotic drug candidates.
Notably, most antithrombotic proteins exhibit significant interspecific divergence. Although prior studies [22] have delineated hirustasin gene superfamily expression patterns within single species, a systematic cross-species expression comparison remains unreported. To further explore the pharmacological activities and therapeutic potential of H. manillensis and W. pigra, we integrated RNA-Seq datasets from both medicinal leech species and conducted a systematic cross-species comparison of expression levels within the hirustasin gene superfamily to identify candidate genes with potential functional relevance. It should be emphasized that transcriptomic analyses primarily serve to nominate putative functional candidates by revealing differences at the mRNA level, which do not necessarily correspond to physiological activity or anticoagulant efficacy. Previous studies have shown that the mRNA abundance (e.g., TPM) of certain leech anticoagulant factors exhibits a partial correlation with protein abundance or anticoagulant activity [26], although this correspondence is not absolute. The findings of the present study provide a valuable foundation for subsequent protein-level validation and the development of novel antithrombotic therapeutics.

2. Materials and Methods

2.1. The RNA Sequencing

Live specimens of H. manillensis were collected from four Chinese localities: Liuzhou, Guangxi (24°18′ N, 109°24′ E); Zhanjiang, Guangdong (21°12′ N, 110°24′ E); Honghe, Yunnan (23°23′ N, 103°23′ E); and Ding’an, Hainan (19°46′ N, 110°27′ E). W. pigra specimens were obtained from four additional sites: Wuhan (30°33′ N, 114°18′ E) and Zhongxiang (31°07′ N, 112°38′ E) in Hubei Province; Baodi, Tianjin (39°43′ N, 117°30′ E); and Yibin, Sichuan (28°45′ N, 104°36′ E). All individuals were captured alive, with sampling site coordinates recorded via GPS. Sample collection was conducted from May to July 2023, corresponding to the main active season of leeches. The sampling sites were shallow freshwater habitats, including ponds, paddy fields, and irrigation ditches, with ambient water temperatures ranging from 25 °C to 30 °C. All specimens were wild-caught and morphologically identified on-site to confirm species identity. A total of 10 individuals were collected from each geographic population, resulting in 80 samples in total (2 species × 4 populations × 10 individuals). Immediately after collection, the specimens were dissected to remove the digestive tract, and tissue samples were stored at −80 °C to prevent RNA degradation. Total RNA was isolated from cephalic tissues using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and purified with the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). High-integrity RNA samples were used to construct cDNA libraries (avg. insert size: 350 bp) with Illumina-compatible reagents. RNA sequencing was performed on the BGISeq platform. Raw reads were quality-controlled using fastp v0.20.0 [27], yielding high-quality clean reads for downstream analyses.

2.2. Expression Analysis of Hirustasin Gene Superfamily

All coding sequences (CDSs) derived from whole-genome structural annotation served as reference templates. A sequence index was constructed using Salmon [28], to which transcriptomic reads were mapped (k-mer size = 31). Gene expression was quantified as transcripts per million (TPM), representing normalized relative transcript abundance. The cumulative TPM values of all hirustasin gene superfamily members per sample were summed to represent total superfamily gene expression.
This study compared total hirustasin gene superfamily gene expression between H. manillensis and W. pigra using the Mann–Whitney U test. To validate statistical method appropriateness, data normality was first assessed via the Shapiro–Wilk test. Given confirmed non-normality, the non-parametric Mann–Whitney U test was subsequently applied for comparative analysis of non-normally distributed data. This methodological choice guaranteed statistical rigor and analytical reliability. Data visualization was performed in RStudio v2024.12.1 [29] using R v4.4.2 [30] and ggplot2 v3.5.2 [31].
For the relative expression analysis of transcriptome data, statistical analyses were conducted using SPSS 26.0 (IBM Corp., Armonk, NY, USA) [32]. The mean ± SE values were calculated for each member of the hirustasin gene superfamily in Hirudinaria manillensis and Whitmania pigra. Pie charts were produced in Origin 2021 (OriginLab Corporation, Northampton, MA, USA) [33] to illustrate the proportion of dominantly expressed genes (TPM > 1000) relative to the total expression of the gene family in each species. Eight dominantly expressed genes with TPM > 1000 were subsequently selected for comparison. The Shapiro–Wilk test revealed that the data did not meet the assumptions of normality and homogeneity of variance; therefore, non-parametric methods were applied for statistical analysis. The Kruskal–Wallis test was used to evaluate significant differences in gene expression among the eight dominant genes. Normalized TPM data were visualized as bar plots using GraphPad Prism 10.1.2 (GraphPad Software, San Diego, CA, USA) [34], revealing differential gene expression patterns of hirustasin gene superfamily members.

2.3. Phylogenetic Analysis of the Hirustasin Gene Superfamily in H. manillensis and W. pigra

Amino acid sequences of the hirustasin gene superfamily from H. manillensis and W. pigra were collected and aligned using MEGA X v10.2 [35] with the ClustalW algorithm under default parameters. The resulting multiple sequence alignment was saved in FASTA format and used as the input for phylogenetic analysis in IQ-TREE v2.2.0 [36]. Phylogenetic trees were constructed using the Maximum Likelihood method, with the best-fit substitution model automatically selected by the ModelFinder module based on the Bayesian Information Criterion. Branch support was assessed using 1000 ultrafast bootstrap replicates. The resulting phylogenetic tree was visualized using FigTree v1.4.4 [37], and graphical refinement and annotation were performed with Inkscape v1.2.2 [38]. Based on the phylogenetic tree, the hirustasin gene superfamily members from H. manillensis and W. pigra were classified into nine monophyletic clades, designated B1 through B9. Interspecies differences in gene expression within each clade were evaluated using the Mann–Whitney U test.

2.4. Analysis of Expression Between Populations

The gene expression of hirustasin gene superfamily members from H. manillensis and W. pigra was combined for population-level analysis. Using SPSS 26.0 (IBM Corp., Armonk, NY, USA) [32], the mean ± standard error (Mean ± SE) of each gene was calculated for different populations within each species. The Shapiro–Wilk test was then performed, and the results indicated that the data did not meet the assumptions of normality and homogeneity of variance. Therefore, non-parametric statistical methods were deemed appropriate for subsequent analysis. The Kruskal–Wallis test was applied via the “Analyze” → “Nonparametric Tests” → “Independent Samples” module to evaluate whether significant differences existed in the total gene expression of the hirustasin gene superfamily among populations within each species, as well as in the gene expression of dominant genes across populations in both species. Finally, a hierarchical clustering heatmap was generated using TBtools-II (Toolbox for Biologists) v2.327 [39]. Row normalization was performed using Z-score transformation, and the clustering algorithm was based on Euclidean distance with average linkage.

3. Results

3.1. Comparison of Expression Between Species

To compare the overall expression differences of the hirustasin gene superfamily between the two species, we first analyzed the total gene expression. The total gene expression (TPM) of the hirustasin gene superfamily in H. manillensis was 11,802.60 ± 1596.59, while in W. pigra, it was 8623.12 ± 965.96 (Supplementary Tables S1 and S2). Shapiro–Wilk tests revealed that the data from both H. manillensis (p = 0.000) and W. pigra (p = 0.004) significantly deviate from normal distribution. Therefore, the non-parametric Mann–Whitney U test was used for statistical comparison. The result showed no significant difference between the two species (Z = −1.184, p = 0.237), suggesting that the total gene expression of the hirustasin gene superfamily were not statistically different between H. manillensis and W. pigra. As shown in Figure 1, the gene expression in H. manillensis displayed considerable inter-sample variability, with a wider violin plot contour and extended tails at both high and low gene expression, indicating a dispersed distribution and potentially greater biological variability. In contrast, W. pigra exhibited a narrower contour, reflecting a more concentrated expression distribution across samples, which may suggest tighter regulatory control of hirustasin gene expression in this species.
Comparative analysis of individual gene expression revealed highly skewed distributions within the hirustasin gene superfamily of both H. manillensis and W. pigra, despite comparable total expression (Table 1). Genes with TPM > 1000 were classified as dominantly expressed genes, yielding five such genes in H. manillensis (hirustasin_like_Hman01, hirustasin_like_Hman04, hirustasin_like_Hman11; guamerin_Hman; poecistasin_Hman2) and three in W. pigra (hirustasin_like_Wpig5; guamerin_Wpig; bdellastasin_Wpig). The homologs of these dominantly expressed genes have been confirmed in previous studies to participate in key hemostatic regulatory processes. Both hirustasin_like_Hman01 and hirustasin_like_Hman04 contain a typical Kunitz-type serine protease inhibitor domain and show high sequence similarity to the reported Hirustasin protein, suggesting that they may inhibit tissue kallikrein and neutrophil proteases, thereby contributing to anti-inflammatory and immune-regulatory functions [17]. Hirustasin_like_Hman11 shares high similarity with the characterized poeciguamerin sequence, which exhibits both anticoagulant and anti-inflammatory activities, indicating that this gene may possess dual functionality [40]. Hirustasin_like_Wpig5, guamerin_Wpig, and guamerin_Hman show strong homology to Guamerin-like proteins, which have been identified as inhibitors of coagulation factor Xa (FXa); thus, these genes are likely to play major roles in anticoagulation by blocking FXa activity [15,18]. The homolog of poecistasin_Hman2 has been reported to inhibit platelet aggregation, suggesting a potential involvement in antiplatelet mechanisms [20]. The homolog of bdellastasin_Wpig is known to specifically inhibit thrombin, implying that it may directly interfere with the terminal step of the coagulation cascade [19]. These dominant genes accounted for a substantial proportion of the total expression—representing 81% in H. manillensis and 62% in W. pigra (Figure 2)—further underscoring their significance as reference candidates for anticoagulant gene screening.
Subsequently, the eight dominantly expressed genes—guamerin_Hman, poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman04, hirustasin_like_Hman11, guamerin_Wpig, bdellastasin_Wpig, and hirustasin_like_Wpig5—were subjected to Kruskal–Wallis analysis. The results revealed highly significant differences among these genes (H = 37.407, df = 7, p < 0.001). Pairwise comparisons indicated that guamerin_Hman significantly differed from hirustasin_like_Hman01, hirustasin_like_Hman11, and guamerin_Wpig, while hirustasin_like_Hman04 also showed significant differences from hirustasin_like_Hman11 and guamerin_Wpig. These findings suggest that these genes are of particular interest and warrant further investigation (Figure 3).

3.2. Phylogenetic Relationships of Hirustasin Gene Superfamily in H. manillensis and W. pigra

To assess phylogenetic correspondence of the dominantly expressed genes, we constructed a hirustasin gene superfamily phylogeny (Figure 4 and Supplementary Data S1). The tree revealed intermingled clustering of H. manillensis and W. pigra sequences across clades. Crucially, most dominantly expressed genes lacked phylogenetically conserved orthology (Table 2), with no evidence of co-dominant expression in closely related ortholog pairs. Mann–Whitney U tests further demonstrated significant interspecific expression differences in all clades except B8 (where expression was comparable). Collectively, these results indicate that H. manillensis and W. pigra exhibit species-specific expression patterns within the hirustasin gene superfamily.
Subsequently, for each monophyletic clade exhibiting dominant gene expression in at least one species, we selected one representative gene per species. With the exception of B1, the gene expression of representative genes from the remaining clades showed substantial differences between H. manillensis and W. pigra. We further screened for genes with TPM values greater than 1000 and found overlap with previously screened dominantly expressed genes, including poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, and bdellastasin_Wpig (Table 3). Moreover, we found that the gene expression of representative genes from monophyletic clades in H. manillensis was generally higher than that in W. pigra, suggesting a potential correlation between blood-feeding behavior and the upregulation of anticoagulant genes. This pattern also implies a link between gene expression, gene function, and evolutionary relationships.

3.3. Comparison of Expression Between Populations

To compare the population gene expression of the hirustasin gene superfamily in H. manillensis and W. pigra, Kruskal–Wallis tests were performed. The results revealed significant differences in total gene expression among geographic populations for both species. In H. manillensis, the difference was highly significant (H = 19.055, df = 3, p < 0.001), and in W. pigra as well (H = 17.501, df = 3, p = 0.001). However, hierarchical clustering heatmaps demonstrated contrasting inter-population patterns (Figure 5). The clustering of H. manillensis populations was more distinct and aligned with geographic origins, whereas W. pigra populations exhibited less defined clustering. Notably, the Ding’an, Hainan H. manillensis population displayed significantly higher average gene expression than other populations (Table 4). This suggests region-specific H. manillensis populations may possess enhanced pharmacological potential, underscoring the importance of daodi medicinal properties—where specific geographic origins confer superior therapeutic quality in traditional medicine. These findings provide critical insights for evaluating regional authenticity and ethnopharmacological value of H. manillensis.
We further observed that all previously identified dominant genes, except bdellastasin_Wpig (H = 7.169, df = 3, p = 0.067), exhibited significant expression differences among geographic populations within their species. Specifically, hirustasin_like_Hman01 (H = 24.745, df = 3, p < 0.001), hirustasin_like_Hman11 (H = 25.073, df = 3, p < 0.001), and poecistasin_Hman2 (H = 19.889, df = 3, p < 0.001) in H. manillensis, along with guamerin_Wpig (H = 14.033, df = 3, p = 0.003) in W. pigra, showed significant inter-population expression variation (Table 4 and Table 5). These five genes may thus serve as key molecular markers for daodi properties in leech-derived materials, likely driving regional variations in pharmacological efficacy observed in traditional medicines.

4. Discussion

Cardiovascular disease remains the leading cause of death globally [2], and currently available antithrombotic drugs are often associated with adverse effects such as bleeding and hepatotoxicity [6]. Therefore, the development of more effective and safer therapeutic agents has become an urgent priority. This study focused on the hirustasin gene superfamily in two medicinal leech species—H. manillensis, a traditional hematophagous species, and W. pigra, a non-hematophagous species listed in the Pharmacopoeia of the People’s Republic of China. Through multidimensional expression analyses, we screened key pharmacologically relevant genes, providing a molecular basis for the discovery and development of novel antithrombotic agents.

4.1. Legitimacy of the Basic Sources of H. manillensis and W. pigra as Medicinal Leeches

The legitimacy of a medicinal material’s basic source refers to the extent to which its source species is officially recognized by national or regional pharmacopoeias, supported by historical documentation, taxonomic accuracy, pharmacological validation, and compliance with safety standards. H. manillensis and W. pigra are the two most common leech species in the Chinese medicinal market, valued for their rapid growth and large body size. However, their medicinal attributes and regulatory status differ markedly. Owing to its hematophagous behavior, H. manillensis is generally considered by the scientific and medical communities to be a superior source of antithrombotic compounds and is presumed to possess greater therapeutic potential, arguably fulfilling ethnopharmacological and scientific criteria for legitimacy. Yet, despite its documented historical usage and modern pharmacological evidence, it has not been included in the Pharmacopoeia of the PPRC [11], and its legal recognition is currently confined to provincial drug standards in regions such as Yunnan and Guangxi [41,42]. From a national regulatory perspective, it remains outside the category of statutory medicinal materials, imposing additional approval requirements and costs for pharmaceutical development. In contrast, W. pigra, although non-hematophagous and feeding mainly on mollusks, meets the historical and morphological definitions of “Mazhi” in classical materia medica, has been listed in the PPRC since 1963, and is fully recognized at the national level as a legitimate basic source species of medicinal leeches [10,43,44]. Importantly, our recent studies have repeatedly confirmed that W. pigra retains substantial antithrombotic activity [45,46], further supporting its continued legal inclusion as a pharmacopeial basic source species. This dichotomy illustrates that while both species possess substantial ethnopharmacological and scientific legitimacy as basic sources, only W. pigra currently enjoys complete legal legitimacy under national standards, whereas H. manillensis remains legally limited despite its pharmacological merits. Given the growing body of molecular, pharmacological, and clinical evidence, we recommend that H. manillensis be considered for inclusion in the PPRC to standardize its application and facilitate its safe, effective use in modern medicine.
Our findings indicate that, despite the pronounced dietary divergence between the two species, the overall gene expression of the hirustasin gene superfamily does not differ significantly. We speculate that the ancestors of W. pigra possessed anticoagulant capacities comparable to those of medicinal leeches, and that the relatively recent shift in feeding habits has not yet led to a comprehensive down-regulation or loss of antithrombotic genes. However, high gene expression does not invariably correspond to high protein yield or potent bioactivity. For instance, although the genome of W. pigra contains seven hirudin genes compared to only five in H. manillensis, previous studies have demonstrated that three of the five hirudins in H. manillensis exhibit pronounced anticoagulant activity, whereas only one of the seven in W. pigra displays comparable anticoagulant activity [22,47]. Although no significant difference was observed in the overall gene expression of the hirustasin gene superfamily between H. manillensis and W. pigra, it is premature to conclude comparable anticoagulant efficacy based solely on gene expression data. Subsequent validation through recombinant protein expression, functional assays, and related experiments is essential. These investigations will establish a robust scientific foundation for the rational selection of raw materials and facilitate the development of effective antithrombotic therapeutics.

4.2. Daodi Medicinal Properties of Medicinal Leeches

From a pharmaceutical perspective, the stability of the geographical source of medicinal materials is also a key determinant of both therapeutic efficacy and safety. Inconsistent raw material quality can result in unpredictable pharmacological effects—either subtherapeutic outcomes due to insufficient dosing or adverse reactions from overdosing. Our findings reveal that although significant differences exist among regional populations of both H. manillensis and W. pigra, the expression patterns of the hirustasin gene superfamily in H. manillensis exhibit strong geographic cohesion. Individuals from the same populations (e.g., YNHH and HNDA) tend to cluster together based on gene expression patterns. In contrast, W. pigra populations from different regions show weak clustering, indicating a lower degree of regional differentiation. These observations suggest that the two species should be treated differently with respect to raw material stability and daodi medicinal properties. For W. pigra, geographic origin may not be a critical factor in evaluating its medicinal value. However, for H. manillensis, regional origin should be considered an essential variable [45]. Future research should conduct more detailed experimental studies on inter-population differences in H. manillensis, including gene expression analysis, recombinant protein production, and functional assays, to identify populations with the strongest anticoagulant potential. Ultimately, the region with the most bioactive population should be designated as the core production area for H. manillensis, thereby laying the foundation for standardized variety development.
The well-known principle that “high-quality medicine comes from high-quality medicinal materials” reflects a fundamental truth in traditional medicine. With the increasing industrialization and commercialization of traditional Chinese medicine (TCM), concerns surrounding the quality and consistency of medicinal materials and decoction pieces have become more pronounced. Many people erroneously attribute the perceived instability in TCM efficacy to deficiencies in TCM theory itself. In reality, the instability should be attributed to the poor quality of medicinal materials (specifically, issues with their geographical origin), not to flaws in traditional Chinese medicine. The quality of medicinal materials is not only closely related to species identity but also heavily influenced by their geographic origin, which determines the biosynthesis and accumulation of active constituents in medicinal plants and animals. In China, many commonly used TCMs are distributed across broad geographic ranges. However, variations in topography, soil type, climate, water quality, and ecosystem conditions across eastern, western, southern, northern, and central regions often lead to significant differences in the quality of the same medicinal species. In some cases, these differences can be substantial. For example, the content of puerarin in Puerariae lobatae Radix can vary from 0.55% to 7.78% depending on the production region—a more than 14-fold difference [48]. Similarly, the antimalarial compound artemisinin in Artemisia annua shows dramatic geographic variation in its content across China, from Hainan Island in the south to Heilongjiang in the north [49]. In Morindae officinalis Radix, the accumulation of bioactive compounds is significantly influenced by ecological factors such as geographic environment, temperature, humidity, and soil conditions, leading to considerable differences in quality across production areas [50]. Such variability in medicinal material quality inevitably translates into inconsistent clinical outcomes. There is growing recognition both domestically and internationally that the stability and daodi origin of medicinal materials are equally as important as the drug itself in determining efficacy. In response, the National Medical Products Administration of China has issued the Good Agricultural Practices (GAP) for Medicinal Materials, which emphasizes the establishment of production bases in ecologically optimal regions for high-quality medicinal cultivation. In this context, our study provides essential technical evidence to support the scientific evaluation of daodi properties in medicinal leeches, offering a foundation for improving consistency, efficacy, and the traceability of TCM raw materials.

4.3. Dominantly Expressed Genes

In drug development, cost and efficiency are equally critical considerations. Numerous antithrombotic compounds have been identified in leeches [15,16], and most antithrombotic proteins are derived from multigene families [51], whose members often exhibit high sequence and functional similarity. Given the size and redundancy of these families, it would be prohibitively time- and resource-intensive to conduct comprehensive biochemical and functional characterization of every gene member. Moreover, indiscriminate targeting of entire gene families may result in off-target effects and unintended physiological disturbances due to the simultaneous modulation of structurally similar isoforms [52]. To date, 13 members of the hirustasin gene superfamily have been identified in the W. pigra genome [47], and 18 members in the H. manillensis genome [22]. In this context, prioritizing dominantly expressed genes with distinct evolutionary characteristics based on gene expression and phylogenetic relationships provides a rational and efficient strategy to improve the feasibility and success of downstream experimental validation. This strategy—“from broad to focused, from many to few”—is essential for the effective development of therapeutics targeting multigene families.
Phylogenetic analysis in this study revealed substantial overlap between H. manillensis and W. pigra in the hirustasin gene superfamily. Most gene clades—such as monophyletic groups B1, B2, B3, B4, B6, and B8—showed mixed distributions between the two species. This pattern may reflect the retention of ancestral genes; prior to speciation, both species likely inherited functionally conserved hirustasin genes whose core domains have maintained their ability to target coagulation factors throughout evolution. The high evolutionary conservation indicates the functional significance of these genes [53], suggesting that those exhibiting interspecific convergence may play critical biological roles. In general, genes with higher gene expression are presumed to contribute more substantially to the pharmacological activity of medicinal resources. Through multi-level comparative analyses of gene expression, we comprehensively examined interspecific differences in the hirustasin gene superfamily between H. manillensis and W. pigra. Ultimately, we screened five dominantly expressed genes (hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, poecistasin_Hman2, and bdellastasin_Wpig) as the most promising candidates with potential medicinal value.
Among the five candidate genes screened as having the highest medicinal potential, poecistasin from H. manillensis has been previously confirmed to possess biological activity and was thus selected as a key gene for experimental investigation [20]. Additionally, hirustasin_like_Hman11 shares high sequence similarity with the previously reported poeciguamerin [40]. The latter has demonstrated dual analgesic and antithrombotic activity [40], suggesting that hirustasin_like_Hman11 may also represent a highly valuable candidate gene. Hirustasin_like_Hman01 is the most abundantly expressed gene within the hirustasin gene superfamily of H. manillensis, and it is located in the core phylogenetic branch (clade B8). However, this gene has never been reported before, and its functional properties remain unknown. Therefore, elucidating the reason behind the unusually high gene expression of hirustasin_like_Hman01 and determining whether it possesses bioactivity will be the primary focus of our subsequent investigations. We plan to perform recombinant protein expression and conduct comprehensive functional experiments to verify its biological activity. If potent bioactivity can be demonstrated, this gene may hold considerable development potential and could even serve as a key biomarker for evaluating the medicinal quality of H. manillensis. The guamerin gene has been repeatedly validated for its analgesic and anti-inflammatory effects in Hirudo nipponia (Korean medicinal leech), leading us to speculate that it may exhibit similar activities in W. pigra [15]. Bdellastasin was first reported in the European medicinal leech Hirudo medicinalis [19,54], but has received little attention in subsequent studies. Interestingly, our phylogenetic analysis revealed that bdellastasin sequences are highly conserved, consistently forming a distinct monophyletic group across species. This suggests that bdellastasin_Wpig may also retain conserved functions and holds considerable pharmacological value.

5. Conclusions

In this study, we systematically compared integrated RNA-Seq data of the hirustasin gene superfamily in two medicinal leech species, H. manillensis and W. pigra, yielding key insights: First, no significant difference was observed in overall hirustasin gene superfamily expression between species (p = 0.237), indicating both possess substantial medicinal potential. Although H. manillensis remains unlisted in the Pharmacopoeia of the People’s Republic of China (PPRC), its pharmacological value warrants serious consideration. Second, pronounced intra-species gene expression variation exists, with dominant genes accounting for 81% (H. manillensis) and 62% (W. pigra) of total expression. This highly unbalanced expression pattern lacks clear phylogenetic conservation. Integrating expression levels and evolutionary positions, we identified five genes with maximal therapeutic promise: poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, and bdellastasin_Wpig—prioritizing these for protein activity validation. Third, dominant genes exhibited significant expression divergence across geographic populations in both species. H. manillensis demonstrated stronger population clustering, suggesting greater region-specific expression traits. These findings underscore the critical importance of daodi medicinal properties in future leech-derived medicinal resource development. Collectively, this study systematically compared the hirustasin gene superfamily between H. manillensis and W. pigra, identified core candidate genes with potential functional significance, and revealed species- and population-specific expression patterns. These findings provide molecular insights into the daodi characteristics of medicinal leeches. Although transcriptomic results do not directly represent physiological activity, this work establishes a molecular framework for exploring the anticoagulant mechanisms of medicinal leeches and offers valuable genetic resources for antithrombotic drug discovery. In the future, integrating expression-based prioritization strategies with structural prediction, molecular docking, computer-aided drug design, and machine learning approaches may help construct a more efficient drug discovery pipeline, thereby supporting the optimized utilization of leech-derived medicinal resources and reducing subsequent development costs.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes16111332/s1, Supplementary Table S1: TPM values of hirustasin gene superfamily members of 40 Hirudinaria manillensis samples; Supplementary Table S2: TPM values of hirustasin gene superfamily members of 40 Whitmania pigra samples; Supplementary Data S1: Full sequences of hirustasin gene superfamily from Hirudinaria manillensis and Whitmania pigra used in this study.

Author Contributions

Conceptualization, F.Z. and G.L.; methodology, R.S., R.A., Z.L. and F.Z.; formal analysis, R.S., J.Y. and J.C.; investigation, R.S., R.A., J.C., L.T. and Z.L.; resources, L.T., Q.Z. and G.L.; data curation, R.A., J.Y. and J.C.; writing—original draft preparation, R.S.; writing—review and editing, R.S., F.Z. and G.L.; visualization, R.S., R.A. and J.Y.; supervision, F.Z.; project administration, Z.H., Q.Z. and G.L.; funding acquisition, Z.H. and G.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (grant number 82260742); the Foundation of Yunnan International Joint Laboratory with South and Southeast Asia for the Integrated Development of Animal-derived Anti-thrombosis Chinese Medicine (grant number 202503AP140025); and the Foundation of Key Laboratory of Jiangxi Province for Biological Invasion and Biosecurity (grant number 2023SSY02111).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding authors.

Acknowledgments

The authors thank the Key Laboratory of Biological Invasion and Biosecurity of Jiangxi Province for the support provided during this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
W. pigraWhitmania pigra (Whitman, 1884)
H. manillensisHirudinaria manillensis (Lesson, 1842)
TPMtranscripts per million
CVDscardiovascular diseases
PPRCPharmacopoeia of the People’s Republic of China
TCMtraditional Chinese medicine
CDSscoding sequences
SEstandard error
GXLZLiuzhou, Guangxi
GDZJZhanjiang, Guangdong
HNDADing’an, Hainan
YNHHHonghe, Yunnan
HBZXZhongxiang, Hubei
TJBDBaodi, Tianjin
SCYBYibin, Sichuan
HBWHWuhan, Hubei

References

  1. Mensah, G.A.; Fuster, V.; Murray, C.J.L.; Roth, G.A. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J. Am. Coll. Cardiol. 2023, 82, 2350–2473. [Google Scholar] [CrossRef] [PubMed]
  2. Lin, L.; Liu, J.; Zhou, M. Top 10 Causes of Death and the Most Growing Causes During the Chinese Spring Festival Holiday—China, 2017–2021. China CDC Wkly. 2023, 5, 68–69. [Google Scholar] [CrossRef]
  3. Chong, B.; Jayabaskaran, J.; Jauhari, S.M.; Chan, S.P.; Goh, R.; Kueh, M.T.W.; Li, H.; Chin, Y.H.; Kong, G.; Anand, V.V.; et al. Global burden of cardiovascular diseases: Projections from 2025 to 2050. Eur. J. Prev. Cardiol. 2024, 32, 1001–1015. [Google Scholar] [CrossRef]
  4. Alarabi, A.B.; Khasawneh, F.T.; Alshbool, F.Z. Managing thrombus formation with EL2-5HTVac: A selective vaccination-based approach targeting the platelet serotonin 5-HT2AR. J. Pharmacol. Exp. Ther. 2025, 392, 103399. [Google Scholar] [CrossRef]
  5. Mackman, N.; Bergmeier, W.; Stouffer, G.A.; Weitz, J.I. Therapeutic strategies for thrombosis: New targets and approaches. Nat. Rev. Drug Discov. 2020, 19, 333–352. [Google Scholar] [CrossRef]
  6. Cheng, Y.; Wang, Y.; Song, Q.; Qiu, K.; Liu, M. Use of anticoagulant therapy and cerebral microbleeds: A systematic review and meta-analysis. J. Neurol. 2021, 268, 1666–1679. [Google Scholar] [CrossRef] [PubMed]
  7. Wu, S.; Zhou, Y.; Wang, Y.; Zhang, Z. Therapeutic Potentials of Medicinal Leech in Chinese Medicine. Am. J. Chin. Med. 2024, 52, 1027–1051. [Google Scholar] [CrossRef]
  8. Wang, Y.; Liu, J.Y.; Liu, S.Q. Research progress on action mechanism of leech in the treatment of cardiovascular and cerebrovascular diseases. China Med. Her. 2021, 18, 47–50. [Google Scholar]
  9. Zaidi, S.M.; Jameel, S.S.; Zaman, F.; Jilani, S.; Sultana, A.; Khan, S.A. A systematic overview of the medicinal importance of sanguivorous leeches. Altern. Med. Rev. 2011, 16, 59–65. [Google Scholar]
  10. The People’s Republic of China. Pharmacopoeia of the People’s Republic of China: 1963 Edition; People’s Medical Publishing House: Beijing, China, 1964.
  11. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; China Medical Science Press: Beijing, China, 2020. [Google Scholar]
  12. He, C.; Chen, X.; Zhang, X.; Wang, L.; Hu, S. A textual research on Whitmania pigra Whitman as the origin of Hirudo. China Med. Her. 2021, 18, 112–115. [Google Scholar]
  13. Zhang, B.; Wang, B.; Gong, Y.; Yu, X.; Lv, J. Anticoagulant active substances extraction and anti-thrombin activity analysis of several species of leeches. Acta Sci. Natralium Univ. Sunyatseni 2012, 51, 92–96. [Google Scholar]
  14. Borda, E.; Siddall, M.E. Arhynchobdellida (Annelida: Oligochaeta: Hirudinida): Phylogenetic relationships and evolution. Mol. Phylogenetics Evol. 2004, 30, 213–225. [Google Scholar] [CrossRef] [PubMed]
  15. Sig, A.K.; Guney, M.; Uskudar Guclu, A.; Ozmen, E. Medicinal leech therapy—An overall perspective. Integr. Med. Res. 2017, 6, 337–343. [Google Scholar] [CrossRef]
  16. Ma, C.; Li, X.; Chen, H. Research progress in the use of leeches for medical purposes. Tradit. Med. Res. 2021, 6, 15. [Google Scholar] [CrossRef]
  17. Söllner, C.; Mentele, R.; Eckerskorn, C.; Fritz, H.; Sommerhoff, C.P. Isolation and characterization of hirustasin, an antistasin-type serine-proteinase inhibitor from the medical leech Hirudo medicinalis. Eur. J. Biochem. 1994, 219, 937–943. [Google Scholar] [CrossRef]
  18. Jung, H.I.; Kim, S.I.; Ha, K.S.; Joe, C.O.; Kang, K.W. Isolation and characterization of guamerin, a new human leukocyte elastase inhibitor from Hirudo nipponia. J. Biol. Chem. 1995, 270, 13879–13884. [Google Scholar] [CrossRef]
  19. Moser, M.; Auerswald, E.; Mentele, R.; Eckerskorn, C.; Fritz, H.; Fink, E. Bdellastasin, a serine protease inhibitor of the antistasin family from the medical leech (Hirudo medicinalis)—Primary structure, expression in yeast, and characterisation of native and recombinant inhibitor. Eur. J. Biochem. 1998, 253, 212–220. [Google Scholar] [CrossRef]
  20. Tang, X.; Chen, M.; Duan, Z.; Mwangi, J.; Li, P.; Lai, R. Isolation and Characterization of Poecistasin, an Anti-Thrombotic Antistasin-Type Serine Protease Inhibitor from Leech Poecilobdella manillensis. Toxins 2018, 10, 429. [Google Scholar] [CrossRef] [PubMed]
  21. Kim, D.R.; Kang, K.W. Amino acid sequence of piguamerin, an antistasin-type protease inhibitor from the blood sucking leech Hirudo nipponia. Eur. J. Biochem. 1998, 254, 692–697. [Google Scholar] [CrossRef]
  22. Liu, Z.; Zhao, F.; Huang, Z.; Hu, Q.; Meng, R.; Lin, Y.; Qi, J.; Lin, G. Revisiting the Asian Buffalo Leech (Hirudinaria manillensis) Genome: Focus on Antithrombotic Genes and Their Corresponding Proteins. Genes 2023, 14, 2068. [Google Scholar] [CrossRef]
  23. Peng, C. Zhonghua Daodi Yaocai (Daodi Medicinal Materials of China); China Traditional Chinese Medicine Press: Beijing, China, 2013. [Google Scholar]
  24. Liu, X.; Zhang, Y.; Wu, M.; Ma, Z.; Huang, Z.; Tian, F.; Dong, S.; Luo, S.; Zhou, Y.; Zhang, J.; et al. The scientific elucidation of daodi medicinal materials. Chin. Med. 2020, 15, 86. [Google Scholar] [CrossRef]
  25. Zhao, Z.; Guo, P.; Brand, E. The formation of daodi medicinal materials. J. Ethnopharmacol. 2012, 140, 476–481. [Google Scholar] [CrossRef] [PubMed]
  26. Xiao, M.; Zhao, F.; Ye, T.; Ai, R.; Tang, L.; Liu, Z.; Zeng, Q.; Huang, Z.; Lin, G. Comparative Study of Leech-Derived Tryptase Inhibitor Genes in Four Medicinal Leech Species. Biology 2025, 14, 1247. [Google Scholar] [CrossRef] [PubMed]
  27. Grabherr, M.G.; Haas, B.J.; Yassour, M.; Levin, J.Z.; Thompson, D.A.; Amit, I.; Adiconis, X.; Fan, L.; Raychowdhury, R.; Zeng, Q.; et al. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat. Biotechnol. 2011, 29, 644–652. [Google Scholar] [CrossRef]
  28. Patro, R.; Duggal, G.; Love, M.I.; Irizarry, R.A.; Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 2017, 14, 417–419. [Google Scholar] [CrossRef]
  29. RStudio Team. RStudio: Integrated Development Environment for R, Version 2024.12.1; Posit Software, PBC: Boston, MA, USA, 2024. [Google Scholar]
  30. R Core Team. R: A Language and Environment for Statistical Computing, Version 4.4.2; R Foundation for Statistical Computing: Vienna, Austria, 2024. [Google Scholar]
  31. Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: Cham, Switzerland, 2016. [Google Scholar]
  32. IBM Corporation. IBM SPSS Statistics for Windows, Version 26.0; IBM Corporation: Armonk, NY, USA, 2019. [Google Scholar]
  33. OriginLab Corporation. Origin, Version 2021; OriginLab Corporation: Northampton, MA, USA, 2021. [Google Scholar]
  34. GraphPad Software, Inc. GraphPad Prism, Version 10.1.2; GraphPad Software, Inc.: San Diego, CA, USA, 2023. [Google Scholar]
  35. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol. Biol. Evol. 2018, 35, 1547–1549. [Google Scholar] [CrossRef]
  36. Minh, B.Q.; Schmidt, H.A.; Chernomor, O.; Schrempf, D.; Woodhams, M.D.; von Haeseler, A.; Lanfear, R. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol. Biol. Evol. 2020, 37, 1530–1534. [Google Scholar] [CrossRef]
  37. Rambaut, A. FigTree v1.4.4, a Graphical Viewer of Phylogenetic Trees, Version 1.4.4; Institute of Evolutionary Biology, University of Edinburgh: Edinburgh, UK, 2018. [Google Scholar]
  38. The Inkscape Team. Inkscape: Professional Quality Vector Graphics Software, Version 1.2.2; The Inkscape Team: Boston, MA, USA, 2023. [Google Scholar]
  39. Chen, C.; Wu, Y.; Li, J.; Wang, X.; Zeng, Z.; Xu, J.; Liu, Y.; Feng, J.; Chen, H.; He, Y.; et al. TBtools-II: A “one for all, all for one” bioinformatics platform for biological big-data mining. Mol. Plant. 2023, 16, 1733–1742. [Google Scholar] [CrossRef]
  40. Wang, C.; Chen, M.; Lu, X.; Yang, S.; Yang, M.; Fang, Y.; Lai, R.; Duan, Z. Isolation and Characterization of Poeciguamerin, a Peptide with Dual Analgesic and Anti-Thrombotic Activity from the Poecilobdella manillensis Leech. Int. J. Mol. Sci. 2023, 24, 11097. [Google Scholar] [CrossRef]
  41. Guangxi Zhuang Autonomous Region Food and Drug Administration. Zhuang Medicine Quality Standards of Guangxi Zhuang Autonomous Region: Volume II; Guangxi Science and Technology Press: Nanning, China, 2011.
  42. Yunnan Food and Drug Administration. Yunnan Provincial Standards for Traditional Chinese Medicinal Materials; Yunnan Science and Technology Press: Kunming, China, 2013.
  43. Qianbian Shuju. Buwuxue: Dongwu Pian (Natural History: Animals); Xuebu Bianyi Tushuju: Beijing, China, 1908. [Google Scholar]
  44. Wang, Z.W. Zhonghua Dadian: Shengwuxue Dian, Dongwu Fen Dian (Encyclopedia of China: Biology, Zoology Section); Yunnan Education Press: Kunming, China, 2015; pp. 705–724. [Google Scholar]
  45. Lin, G.; Yin, J.; Zhang, W.; Huang, Z.; Liu, Z.; Chen, H.; Tang, L.; Zhao, F. Population Genetics of the Asian Buffalo Leech (Hirudinaria manillensis) in Southern China Based on Mitochondrial Protein-Coding Genes. Biology 2025, 14, 926. [Google Scholar] [CrossRef] [PubMed]
  46. Zhao, F.; Huang, Z.; Tang, L.; Zhang, W.; Liu, Z.; Lin, G. Comparative genomics of three non-hematophagous leeches (Whitmania spp.) with emphasis on antithrombotic biomolecules. Front. Genet. 2025, 16, 1548006. [Google Scholar] [CrossRef]
  47. Liu, Z.; Zhao, F.; Huang, Z.; He, B.; Liu, K.; Shi, F.; Zhao, Z.; Lin, G. A Chromosome-Level Genome Assembly of the Non-Hematophagous Leech Whitmania pigra (Whitman 1884): Identification and Expression Analysis of Antithrombotic Genes. Genes 2024, 15, 164. [Google Scholar] [CrossRef] [PubMed]
  48. Zhong, Y.; Wang, J.; Yang, S.; Tang, W.; Zuo, C. Determination of Puerarin in Pueraria lobata from Different Areas by HPLC. Lishizhen Med. Mater. Medica Res. 2000, 11, 1059–1060. [Google Scholar]
  49. Zhang, X.; Zhao, Y.; Guo, L.; Qiu, Z.; Huang, L.; Qu, X. Differences in chemical constituents of Artemisia annua L. from different geographical regions in China. PLoS ONE 2017, 12, e0183047. [Google Scholar] [CrossRef]
  50. Zhang, R.; Li, Q.; Qu, M.; Gao, J.; Dian, P. Investigation of Morinda officinalis How Oligosaccharides from Different Habitats and Germplasm Resources with Various Ages. Chin. Pharm. J. 2016, 51, 315–320. [Google Scholar]
  51. Kvist, S.; Manzano-Marín, A.; de Carle, D.; Trontelj, P.; Siddall, M.E. Draft genome of the European medicinal leech Hirudo medicinalis (Annelida, Clitellata, Hirudiniformes) with emphasis on anticoagulants. Sci. Rep. 2020, 10, 9885. [Google Scholar] [CrossRef] [PubMed]
  52. Heguy, A.; Stewart, A.A.; Haley, J.D.; Smith, D.E.; Foulkes, J.G. Gene expression as a target for new drug discovery. Gene Expr. 1995, 4, 337–344. [Google Scholar]
  53. Wang, Z.; Zhang, J. Why is the correlation between gene importance and gene evolutionary rate so weak? PLoS Genet. 2009, 5, e1000329. [Google Scholar] [CrossRef]
  54. Rester, U.; Bode, W.; Moser, M.; Parry, M.A.; Huber, R.; Auerswald, E. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system. J. Mol. Biol. 1999, 293, 93–106. [Google Scholar] [CrossRef]
Genes 16 01332 g001
Figure 1. Violin plot with overlaid boxplot showing the total gene expression of the hirustasin gene superfamily in Hirudinaria manillensis (left) and Whitmania pigra (right). The violin plot outlines represent the kernel density distribution of expression values; greater widths indicate a higher density of samples at that gene expression. Overlaid white boxplots indicate the median (bold horizontal line within the box), interquartile range (box boundaries), and whiskers extending to 1.5 × IQR beyond the upper and lower quartiles. Dots outside the whiskers denote outliers. The statistical annotation above the violin plots (p = 0.237, Mann–Whitney U test) indicates that there is no significant difference in total hirustasin gene expression between the two species.
Figure 1. Violin plot with overlaid boxplot showing the total gene expression of the hirustasin gene superfamily in Hirudinaria manillensis (left) and Whitmania pigra (right). The violin plot outlines represent the kernel density distribution of expression values; greater widths indicate a higher density of samples at that gene expression. Overlaid white boxplots indicate the median (bold horizontal line within the box), interquartile range (box boundaries), and whiskers extending to 1.5 × IQR beyond the upper and lower quartiles. Dots outside the whiskers denote outliers. The statistical annotation above the violin plots (p = 0.237, Mann–Whitney U test) indicates that there is no significant difference in total hirustasin gene expression between the two species.
Genes 16 01332 g001
Genes 16 01332 g002
Figure 2. Pie charts showing the proportional expression of dominant members of the hirustasin gene superfamily in H. manillensis and W. pigra ((A), H. manillensis; (B), W. pigra).
Figure 2. Pie charts showing the proportional expression of dominant members of the hirustasin gene superfamily in H. manillensis and W. pigra ((A), H. manillensis; (B), W. pigra).
Genes 16 01332 g002
Genes 16 01332 g003
Figure 3. Bar plots showing gene expression of hirustasin gene superfamily members. (A) Gene expression of hirustasin superfamily genes in H. manillensis. (B) Gene expression of hirustasin superfamily genes in W. pigra. (C) Dominantly expressed hirustasin genes (TPM > 1000) in H. manillensis. (D) Dominantly expressed hirustasin genes (TPM > 1000) in W. pigra.
Figure 3. Bar plots showing gene expression of hirustasin gene superfamily members. (A) Gene expression of hirustasin superfamily genes in H. manillensis. (B) Gene expression of hirustasin superfamily genes in W. pigra. (C) Dominantly expressed hirustasin genes (TPM > 1000) in H. manillensis. (D) Dominantly expressed hirustasin genes (TPM > 1000) in W. pigra.
Genes 16 01332 g003
Genes 16 01332 g004
Figure 4. Phylogenetic relationships among hirustasin gene superfamily members from H. manillensis and W. pigra. Red branches represent dominantly expressed genes in H. manillensis, while blue branches represent dominantly expressed genes in W. pigra.
Figure 4. Phylogenetic relationships among hirustasin gene superfamily members from H. manillensis and W. pigra. Red branches represent dominantly expressed genes in H. manillensis, while blue branches represent dominantly expressed genes in W. pigra.
Genes 16 01332 g004
Genes 16 01332 g005
Figure 5. Hierarchical clustering heatmaps based on the gene expression of hirustasin gene superfamily members across geographic populations of two leech species ((A), H. manillensis; (B), W. pigra). Rows represent geographic populations, and columns represent hirustasin gene superfamily members. Color gradients indicate gene expression, with red representing high gene expression and blue representing low gene expression. The dendrograms reflect the similarity in gene expression patterns among populations.
Figure 5. Hierarchical clustering heatmaps based on the gene expression of hirustasin gene superfamily members across geographic populations of two leech species ((A), H. manillensis; (B), W. pigra). Rows represent geographic populations, and columns represent hirustasin gene superfamily members. Color gradients indicate gene expression, with red representing high gene expression and blue representing low gene expression. The dendrograms reflect the similarity in gene expression patterns among populations.
Genes 16 01332 g005
Table 1. TPM values of hirustasin gene superfamily members in Hirudinaria manillensis and Whitmania pigra (genes with TPM > 1000 are shown in bold).
Table 1. TPM values of hirustasin gene superfamily members in Hirudinaria manillensis and Whitmania pigra (genes with TPM > 1000 are shown in bold).
SpeciesGenesTPM (Mean ± SE)
H. manillensishirustasin_Hman92.72 ± 27.61
guamerin_Hman1059.16 ± 213.26
piguamerin_Hman242.05 ± 75.62
bdellastasin_Hman498.73 ± 50.99
poecistasin_Hman143.12 ± 12.74
poecistasin_Hman21979.36 ± 323.89
hirustasin_like_Hman012608.04 ± 476.68
hirustasin_like_Hman020.05 ± 0.05
hirustasin_like_Hman0340.40 ± 6.97
hirustasin_like_Hman041377.83 ± 346.05
hirustasin_like_Hman05539.67 ± 128.56
hirustasin_like_Hman06350.02 ± 52.86
hirustasin_like_Hman072.53 ± 0.83
hirustasin_like_Hman08360.13 ± 31.59
hirustasin_like_Hman090.10 ± 0.07
hirustasin_like_Hman1053.60 ± 7.49
hirustasin_like_Hman112555.10 ± 330.36
hirustasin_like_Hman120.00 ± 0.00
W. pigrahirustasin_Wpig725.32 ± 109.63
guamerin_Wpig2237.09 ± 234.68
piguamerin_Wpig68.07 ± 22.53
bdellastasin_Wpig1615.72 ± 176.90
hirustasin_like_Wpig1782.95 ± 128.68
hirustasin_like_Wpig2495.12 ± 103.76
hirustasin_like_Wpig3288.65 ± 63.01
hirustasin_like_Wpig4697.36 ± 152.85
hirustasin_like_Wpig51507.97 ± 253.54
hirustasin_like_Wpig6181.25 ± 36.50
hirustasin_like_Wpig712.01 ± 1.87
hirustasin_like_Wpig81.34 ± 0.37
hirustasin_like_Wpig910.27 ± 2.21
TPM, transcripts per million; SE, standard error.
Table 2. Comparison of average gene TPMs between monophyletic clades of H. manillensis and W. pigra (genes with clade-average TPM > 1000 are shown in bold).
Table 2. Comparison of average gene TPMs between monophyletic clades of H. manillensis and W. pigra (genes with clade-average TPM > 1000 are shown in bold).
BranchMonophyletic GroupTPM (Mean ± SE)Mann–Whitney U Test
H. manillensisW. pigraH. manillensisW. pigrap
B1guamerin_Hman
hirustasin_like_Hman08
hirustasin_like_Hman11		guamerin_Wpig
hirustasin_like_Wpig5		1324.80 ± 155.061872.53 ± 176.470.000
B2poecistasin_Hman1
poecistasin_Hman2		—1011.24 ± 194.92——
B3piguamerin_Hmanpiguamerin_Wpig242.05 ± 75.6268.07 ± 22.530.002
B4hirustasin_Hmanhirustasin_Wpig92.72 ± 27.61725.32 ± 109.630.000
B5hirustasin_like_Hman12—0.00 ± 0.00——
B6hirustasin_like_Hman10hirustasin_like_Wpig753.60 ± 7.4912.01 ± 1.870.000
B7bdellastasin_Hmanbdellastasin_Wpig498.73 ± 50.991615.72 ± 176.900.000
B8hirustasin_like_Hman01
hirustasin_like_Hman04
hirustasin_like_Hman05
hirustasin_like_Hman06
hirustasin_like_Hman09		hirustasin_like_Wpig1
hirustasin_like_Wpig2
hirustasin_like_Wpig3
hirustasin_like_Wpig4		975.13 ± 136.89566.02 ± 59.850.192
B9hirustasin_like_Hman02
hirustasin_like_Hman03
hirustasin_like_Hman07		hirustasin_like_Wpig6
hirustasin_like_Wpig8
hirustasin_like_Wpig9		14.32 ± 2.8764.29 ± 14.270.000
TPM, transcripts per million; SE, standard error.
Table 3. Comparison of the TPM of representative genes from monophyletic clades with dominantly expressed genes in H. manillensis and W. pigra (genes with TPM > 1000 are shown in bold).
Table 3. Comparison of the TPM of representative genes from monophyletic clades with dominantly expressed genes in H. manillensis and W. pigra (genes with TPM > 1000 are shown in bold).
BranchRepresentative GeneTPM (Mean ± SE)Mann–Whitney U Test
H. manillensisW. pigraH. manillensisW. pigrap
B1hirustasin_like_Hman11guamerin_Wpig2555.10 ± 330.362237.09 ± 234.680.969
B2poecistasin_Hman2—1979.36 ± 323.89——
B7bdellastasin_Hmanbdellastasin_Wpig498.73 ± 50.991615.72 ± 176.900.000
B8hirustasin_like_Hman01hirustasin_like_Wpig12608.04 ± 476.68782.95 ± 128.680.001
TPM, transcripts per million; SE, standard error.
Table 4. Comparison of the TPM among different geographic populations of H. manillensis (genes with TPM > 1000 are shown in bold).
Table 4. Comparison of the TPM among different geographic populations of H. manillensis (genes with TPM > 1000 are shown in bold).
GenesGXLZGDZJHNDAYNHH
guamerin_Hman36.48 ± 21.1623.99 ± 7.061697.73 ± 373.622478.44 ± 379.26
piguamerin_Hman31.60 ± 5.9942.94 ± 22.19336.70 ± 130.25556.96 ± 245.52
bdellastasin_Hman588.99 ± 123.29285.14 ± 50.86757.15 ± 105.23363.63 ± 28.03
poecistasin_Hman11.16 ± 0.770.35 ± 0.3526.50 ± 8.39144.45 ± 34.22
poecistasin_Hman22027.26 ± 450.901228.96 ± 239.534308.24 ± 762.49352.98 ± 130.15
hirustasin_Hman18.17 ± 6.3220.52 ± 17.59327.05 ± 68.535.12 ± 3.82
hirustasin_like_Hman013208.87 ± 696.96865.97 ± 170.415892.71 ± 1149.24464.60 ± 128.39
hirustasin_like_Hman020.18 ± 0.180.00 ± 0.000.00 ± 0.000.00 ± 0.00
hirustasin_like_Hman0356.58 ± 18.0034.25 ± 11.7166.05 ± 11.414.73 ± 1.61
hirustasin_like_Hman041240.43 ± 312.66545.94 ± 158.503535.01 ± 1094.58189.93 ± 43.14
hirustasin_like_Hman05908.83 ± 185.7935.25 ± 14.401200.87 ± 359.1113.75 ± 9.83
hirustasin_like_Hman06289.22 ± 67.1795.74 ± 16.06534.75 ± 88.00480.38 ± 150.49
hirustasin_like_Hman070.11 ± 0.070.64 ± 0.240.78 ± 0.298.56 ± 2.55
hirustasin_like_Hman08371.95 ± 56.79141.25 ± 20.37476.38 ± 68.14450.94 ± 35.52
hirustasin_like_Hman090.42 ± 0.260.00 ± 0.000.00 ± 0.000.00 ± 0.00
hirustasin_like_Hman1028.02 ± 7.0420.86 ± 3.47108.27 ± 19.2457.25 ± 3.98
hirustasin_like_Hman111169.45 ± 283.54786.68 ± 152.104440.28 ± 668.903824.01 ± 454.00
hirustasin_like_Hman120.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
total9977.47 ± 1972.104128.47 ± 640.1523,708.45 ± 3815.569395.75 ± 1421.22
GXLZ, Liuzhou, Guangxi; GDZJ, Zhanjiang, Guangdong; HNDA, Ding’an, Hainan; YNHH, Honghe, Yunnan.
Table 5. Comparison of the TPM among different geographic populations of W. pigra (genes with TPM > 1000 are shown in bold).
Table 5. Comparison of the TPM among different geographic populations of W. pigra (genes with TPM > 1000 are shown in bold).
GenesHBZXTJBDSCYBHBWH
guamerin_Wpig1270.04 ± 189.421664.56 ± 355.673207.58 ± 354.582806.17 ± 620.90
piguamerin_Wpig7.54 ± 2.37 38.67 ± 16.09 98.46 ± 21.39 127.61 ± 84.12 
bdellastasin_Wpig1330.45 ± 321.411237.76 ± 248.672540.08 ± 445.481354.59 ± 226.68
hirustasin_Wpig285.57 ± 103.50 746.39 ± 191.20 930.92 ± 172.18 938.42 ± 316.45
hirustasin_like_Wpig1325.44 ± 17.90 333.95 ± 94.92 1632.20 ± 314.95840.19 ± 217.86 
hirustasin_like_Wpig236.20 ± 10.60 218.95 ± 68.79 1133.99 ± 224.77591.34 ± 230.18 
hirustasin_like_Wpig371.26 ± 14.58 118.98 ± 36.86 638.90 ± 169.57 325.47 ± 127.52 
hirustasin_like_Wpig4121.26 ± 54.36 271.15 ± 85.52 1550.02 ± 414.79847.01 ± 286.88 
hirustasin_like_Wpig5253.76 ± 38.68 876.63 ± 156.97 2000.35 ± 450.542901.13 ± 650.71
hirustasin_like_Wpig681.80 ± 18.92 209.64 ± 72.76 64.51 ± 8.90 369.06 ± 103.62 
hirustasin_like_Wpig76.90 ± 1.70 9.26 ± 2.10 7.51 ± 2.49 24.37 ± 4.92 
hirustasin_like_Wpig82.72 ± 1.28 1.71 ± 0.43 0.14 ± 0.10 0.78 ± 0.39 
hirustasin_like_Wpig914.14 ± 3.48 25.51 ± 4.92 0.64 ± 0.28 0.81 ± 0.66 
total3807.07 ± 504.965753.17 ± 1201.5913,805.31 ± 1621.1511,126.94 ± 2161.89
HBZX, Zhongxiang, Hubei; TJBD, Baodi, Tianjin; SCYB, Yibin, Sichuan; HBWH, Wuhan, Hubei.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sun, R.; Ai, R.; Yin, J.; Cheng, J.; Huang, Z.; Tang, L.; Liu, Z.; Zeng, Q.; Zhao, F.; Lin, G. Comparative Study of Hirustasin Superfamily Gene Expression in Two Medicinal Leeches, Hirudinaria manillensis and Whitmania pigra. Genes 2025, 16, 1332. https://doi.org/10.3390/genes16111332

AMA Style

Sun R, Ai R, Yin J, Cheng J, Huang Z, Tang L, Liu Z, Zeng Q, Zhao F, Lin G. Comparative Study of Hirustasin Superfamily Gene Expression in Two Medicinal Leeches, Hirudinaria manillensis and Whitmania pigra. Genes. 2025; 16(11):1332. https://doi.org/10.3390/genes16111332

Chicago/Turabian Style

Sun, Rujiao, Rui Ai, Jingjing Yin, Jianli Cheng, Zuhao Huang, Lizhou Tang, Zichao Liu, Qingqian Zeng, Fang Zhao, and Gonghua Lin. 2025. "Comparative Study of Hirustasin Superfamily Gene Expression in Two Medicinal Leeches, Hirudinaria manillensis and Whitmania pigra" Genes 16, no. 11: 1332. https://doi.org/10.3390/genes16111332

APA Style

Sun, R., Ai, R., Yin, J., Cheng, J., Huang, Z., Tang, L., Liu, Z., Zeng, Q., Zhao, F., & Lin, G. (2025). Comparative Study of Hirustasin Superfamily Gene Expression in Two Medicinal Leeches, Hirudinaria manillensis and Whitmania pigra. Genes, 16(11), 1332. https://doi.org/10.3390/genes16111332

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop